Organ transplant & the psychiatrist: An overview

B.N. Anil Kumar* & Surendra Kumar Mattoo

Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh, India

Received April 25, 2013

Organ transplantation has emerged as the saving grace for those who are suffering from end organ disease. Advent of modern surgical procedures and immunosuppressants further decrease morbidity and mortality. Meta-analyses have shown that post-organ transplantation quality of life improves for social, physical and daily activity functioning, but not consistently for psychological health. Psychi atrists can play a useful role not only in selecting the best suitable candidate for the procedure by psychosocial screening but also to tackle post-operation psychological issues that trouble patients as well as caretakers and decrease their quality of life. Issues like selection of patients with psychiatric disorders and substance abuse for transplantation process and their treatment both pre- and post- operation, risky health behaviours, treatment adherence for immunosuppressants and psychological support for caretakers can be better addressed by a psychiatrist who is sensitive towards these issues. Prescribing various psychotropics and immunosuppressants in the background of impaired organ function and drug-drug interaction is further challenging. Thus, psychiatrists need to be knowledgeable about these issues and should be an integral part of organ transplantation team for overall better outcome.

Key words Organ transplantation - psychiatrist - psychiatric disorders - quality of life - substance abuse

Introduction

Organ transplant/transplantation (OT) has been defined as the therapeutic grafting of an organ from a living or dead body to a living body1. OT is a complex, invasive and major surgical procedure which carries tremendous expectations from the OT candidates and caregivers for saving life and improving the quality of life (QOL). Thus, starting from the onset of the end stage organ disease (ESOD), undergoing evaluation for candidacy, surgical procedure and related complications, and ending with death, all through these phases OT and organ donation are inherently enormously distressing. Also, OT is bound to ethical and legal issues. In the developing countries, the picture gets complicated by the psychosocial milieu being different in terms of poverty, underdeveloped protective medical institutional mechanisms, family structure and functioning, cultural norms and values related to organ donating/receiving. Emerging evidence shows that pre-operative psychosocial variables can predict post-transplant psychiatric adjustment for most organ types2, and meta-analyses have shown that post-transplant QOL improves for social, physical and daily activity functioning, but not

*Present address: Department of Psychiatry, Shridevi Institute of Medical Sciences & Research Hospital, Tumkur, Karnataka, India
consistently for psychological health\textsuperscript{3,4}. This implies that while medico-surgical teams take better care of the physical health, they may leave out the psychological perspective. The medico-surgical teams may overlook psychological distress, especially if underplayed by the subjects.

This overview highlights the psychiatrist’s perspective on psychosocial and medication issues related to the organ recipients, donors, and caregivers, and their effect on the OT outcome. The aim is to highlight the role of the psychiatrist and to sensitize the medical fraternity in general and the OT teams in particular. The literature search strategies included electronic databases and manual searches of relevant publications or cross-references. Electronic search included PubMed and other search engines (Embase, Science Direct, Google Scholar) for the years 2005-2014. Cross-searches often yielded additional relevant material. The search terms used in various combinations were: transplantation, psychiatrist, psychiatry, living donors, caregivers, psychotropics. The relevant articles were selected based on their importance for psychosocial and psychiatric aspects of OT. Accordingly, we selectively focussed on good and large scale relevant reviews and meta-analyses. Thus, this review attempts to give an overview of the area and is not a systematic review of the area\textsuperscript{5}. Relevant Indian research is summarised separately.

Organ transplant: A heavy burden

Organ transplant is a continuum of different phases, each associated with its own individual, social and economic problems.

(i) End stage organ disease (ESOD) is the patient’s worst clinical state with failed organ function. As a matter of life and death, it marks the beginning of OT.

(ii) OT evaluation involves various steps to achieve OT candidacy, at the cost of a performance anxiety and the fear of omission.

(iii) Waiting for organ donation is the most distressing phase. Continued deterioration of health and critical medical care like dialysis is associated with10-18 per cent patients dying, and 5 per cent becoming medically unsuitable; another 2 per cent refuse OT\textsuperscript{6}. The greatest obstacle is the shortage of donated organs; in the USA 40 per cent candidates wait for >2 years before they get an organ\textsuperscript{6}.

(iv) Transplantation and after, means dealing with a complex OT procedure, perioperative complications, and a post-OT life with constant threat to survival, and inevitable and often distressing dependence on caregivers for help on various counts.

Unique dual role of psychiatrist in transplantation

Comprehensive pre-transplant psychosocial evaluation helps to get a more complete understanding of mutual, and sometimes contradictory, expectations and needs of transplant candidates, donors, caretakers and the transplant team. The psychiatrist plays a unique dual role in serving both the needs of the transplant team as well as the transplant patient, donor and the carers\textsuperscript{7}. The psychiatrist also has a major role in identifying problematic areas/issues both pre- and post-transplant and address those to seek improved outcomes.

Pre-transplant psychosocial evaluation

It is a stepping stone for OT candidacy. Limited availability of donor organs, need for psychological sophistication, good family support, considerable medical and financial resources for better care and outcome - all dictate the selection of only those candidates who have the best chance of post-OT outcome. To select the best candidate for transplantation, there is a need to screen the patient’s coping skills for stressors, co-morbid psychiatric conditions and their pre- and post-transplant monitoring and treatment, capacity to understand the transplant process and to provide informed consent, ability to collaborate with the transplant team and to adhere to treatment, substance use/abuse history, recovery, and ability to maintain long-term abstinence, health behaviours that may influence post-transplant morbidity and mortality like eating or exercise habits, level of social support available to the candidate for pre- and post-transplant phases and psychosocial needs of the patient and family and plan for services during the waiting, recovery, and rehabilitation phases of the transplant process\textsuperscript{8}.

Some of the important aspects of organ transplant will be considered in the following sections which demand a psychiatrist’s expertise:

Treatment adherence

Treatment adherence generally includes regular intake of medications, monitoring vitals, undergoing diagnostic tests, following dietary and exercise protocols, abstinence from substance abuse, and regular
follow up. A meta-analysis of 147 studies across all organ types showed average non-adherence per 100 PPY (persons per year) to be 1-4 for substance use, 19-25 for immunosuppressants, diet, exercise, and other requirements.

A review of 17 studies showed non-adherence to be associated with poor clinical outcome, contributing to 20 percent of late acute rejection episodes, lower number of quality adjusted life years and lower lifetime costs because of shorter survival. Thus, it is very essential to identify candidates with ambivalence about treatment and prior history of non-adherence, substance abuse, poor social support, and poor organisational skills as they are more prone for treatment non-adherence.

**Risky health behaviours**

These include substance abuse, poor eating habits and sedentary lifestyle leading to obesity. Studies have shown that pre-transplantation BMI >30 kg/m² or body weight >140 percent of ideal, decrease survival rate among transplant recipients compared to controls among renal and heart cases, respectively. Another study showed that compared to controls nutritional counselling of OT subjects, once weekly for a month and once monthly for next three months, reduced post-transplant weight gain. Presumably poor outcome may be reduced by identifying reasons and risk factors for non-adherence and risky health behaviours, educating patient and family members regarding the same, making plan for monitoring both pre- and post-OT, and written informed behavioural and contingency contracting making the patient responsible for own acts. Recently, efforts have been made to develop a programme based on prevailing evidence to promote self-management skills for behaviours such as undesired weight gain, exercising and smoking.

**Psychiatric disorders among OT cases**

Like other chronically medically ill subjects, OT cases are also at higher risk for psychiatric disorders. It may be due to either the exacerbation of a pre-existing disorder or the development of new-onset disorder. With no large-scale prevalence rate comparisons yet available, no strong evidence exists that in OT the rates of psychiatric disorders vary by the organ.

**Mood and anxiety disorders**

Anxiety or depressive disorders are experienced by 25 percent of lung, 40 percent of liver and 50 percent of heart pre-OT cases. In post-OT cases during the first several years, major depression was experienced by 20 percent of kidney, 30 percent of liver, and 63 percent of heart cases. Compared to pre-OT/waiting period the risk was greatest in the first post-OT year; contributing factor being the stress associated with physical recovery, rehabilitation, adaptation to immunosuppressive medications, and psychosocial role change. Studies have shown that while the patient is in waiting period depressive symptoms are associated with poor QOL, poor adaptive coping, and low functional status, and there is high mortality in patients with depressive symptoms both during pre- or post-transplant period.

Among anxiety disorders during OT, post-traumatic stress disorder (PTSD) is most important. 14-44 percent of ICU-treated cases experience PTSD, with >24 percent having persistent symptoms years later. PTSD may result from any medical crisis during waiting period, surgery itself, and hallucinations and delusions associated with post-surgical delirium. Post-traumatic stress disorder or symptoms are shown to increase mortality, decrease QOL and life satisfaction. With mood and anxiety disorders conclusively predicting higher morbidity and mortality, 45 percent of OT centres in the USA consider current affective disorders as an absolute contraindication for OT.

**Psychotic disorders**

Psychosis emerging beyond post-operative recovery period occurs exclusively in OT cases with past history of such illness. Among such cases, 37 percent experienced manic or psychotic episodes in the first several post-OT years. Hence, there is a need for aggressive pre-OT treatment as psychotic symptoms have a negative impact on OT outcome. However, it remains debatable as to how fair it is to deny organ to a psychotic patient; in the USA, 92.3 percent OT centres consider active schizophrenia as an absolute contraindication for OT.

A survey across 12 OT centres in US, Canada and Australia showed non-compliance with immunosuppressant drugs among psychotic cases living alone to be 45.5 percent, 9.5 percent among psychotic cases living with someone, and 20-50 percent among overall OT cases. Suicide attempts in the pre-OT year were recorded in 35.7 percent cases with psychotic symptoms versus 5.9 percent of those without psychotic symptoms. Thus, it is evident that in cases with psychosis, good social support and adequate pre-OT symptom control mean a better outcome.
Personality disorders

The OT process demands a series of adaptations in physical and social functioning and ability to cooperate with caregivers and OT team. The persisting and inflexible maladaptive patterns of behaviour with personality disorder (PD) cases lead to impaired interpersonal relationship and social functioning.

Incidence of personality disorders among OT cases has been reported to be 10-26 per cent, similar to that in general population. A survey of all active OT programmes in the USA showed that 14.1 per cent of heart, 8.7 per cent of liver, 5.2 per cent of kidney OT programmes viewed personality disorder as an absolute contraindication to OT. Another study showed that borderline personality disorder carries highest risk for post-OT non-compliance, less stable social support and strained working relation with OT team.

In a study in alcoholic liver disease cases with anti-social personality disorder, 50 per cent returned to either alcohol or narcotic addiction compared to 20 per cent with no personality disorder.

Cognitive disorders

Through pre- to post-OT phases, cases frequently experience reductions in cognitive functioning ranging from subclinical to frank delirium. Among OT recipients cognitive impairment remains relevant in terms of potential negative impact on treatment compliance due to patient’s inability to learn old or new instructions/ regimens for medication, investigations and behaviours related to memory deficits, delusions and hallucinations associated with delirium. Perhaps due to these facts dementia is considered as an absolute contraindication among 72 per cent of the US OT centres.

Mental retardation (MR)

There is no scientific evidence suggesting cases with MR should not have access to organ transplantation. Yet, 25.6 and 74.4 per cent OT centres in the USA considered IQ 70-90 and IQ <70, respectively as an absolute contraindication for transplantation. This automatic exclusion of cases with MR from OT continues to be a matter of debate as a clear form of discrimination. A review of cases with MR and renal OT showed post-OT survival rates of 100 per cent at one year and 90 per cent at three years. These rates were similar to those of non-MR cases. This review highlights that adequate support from family and other caregivers rather than the recipient’s IQ level predict post-OT medication compliance.

Substance abuse

In both the USA and Europe the most common indications for liver transplantation are cirrhosis due to alcoholic liver disease (ALD) and hepatitis B and C (HBV, HCV), especially among intravenous drug abusers. The OT teams continue to debate whether or not to offer OT to cases with substance abuse. The major concern is post-OT substance abuse relapse resulting in direct damage to transplanted organ, decreased efficacy of ongoing medical treatment, increased risk for cancer and non-adherence to treatment; all eventually leading to graft failure and recipient death.

Tobacco use in immunosuppressed patients increases risk of cancer. Smoking increases vascular complications among post-OT liver cases (17.8% in smokers vs. 8% in controls). In ALD liver transplant recipients, risk of oropharyngeal and lung cancer was 25 and 3.7 times higher compared to controls. Another study showed transplanted ALD cases had 1- and 5-year survival rates of about 80 and 70 per cent, respectively, comparable to transplants for other causes of cirrhosis. Though there is sufficient evidence to suggest post-OT substance use carries major adverse health consequences, a meta-analysis of 54 studies showed post liver OT relapse to any alcohol use twice more than relapse to heavy alcohol use (~6 vs <3/100 PPY) and non-adherence to immunosuppressant medication being 3.2/100 PPY. These figures are comparable to cases with no prior history of abuse. The pre-transplant history of illicit drug use has not been consistently shown to be associated with increased risk for post-transplant alcohol relapse in ALD recipients, possibly because many ALD recipients had discontinued their drug use many years prior to transplantation. Thus, a history of substance abuse should not be an absolute contraindication for OT. The available research shows cases with history of alcohol abuse that are treated effectively have relapse rate, non-adherence to medications, and survival rates comparable to cases with no such history. More worrying is relapse to tobacco use and associated medical complications. Smoking, both by donors and by recipients, has a major negative impact on outcomes after organ transplantation. The risk factors for relapse include poor social support, family history of alcohol dependence, pre-transplant abstinence of ≤ 6 months, past failed rehabilitation, and multiple substance abuse.

There are no efficacy studies on treatment. General advice is for frequent follow up with random
toxicological screening, motivation enhancement therapy (MET), and relapse prevention counselling (RPC). Among medications, naltrexone being a direct hepatotoxin, is contraindicated in liver failure. Disulfiram is hepatically metabolized and may lead to immunosuppressant toxicity. Selective serotonin reuptake inhibitors (SSRI) and tricyclic antidepressants (TCA) improve abstinence rates in depressed relapsing alcoholics.\textsuperscript{42}

**Immunosuppressant related neuropsychiatric manifestations**

Common immunosuppressants currently used in OT (tacrolimus, cyclosporine, corticosteroids, azathioprine and mycophenolate mofetil), are all well known for their neuropsychiatric side effects.\textsuperscript{46-49}

Calcineurin-inhibiting immunosuppressants (CII): Tacrolimus and cyclosporine have a similar neurotoxic profile: 40-60 per cent recipients have mild symptoms like tremulousness, headache, restlessness, insomnia, vivid dreams, photophobia, dysaesthesias, anxiety, and agitation, and 20-32 per cent have moderate to severe symptoms like cognitive impairment, coma, seizures, focal neurological deficits, dysarthria, cortical blindness, psychosis, and delirium. With discontinuation of CII, most of the side effects resolve spontaneously. Short term anticonvulsants can be used for CII-induced seizures, and benzodiazepines or beta-blockers for anxiety, tremor, or restlessnes.\textsuperscript{42}

Corticosteroids: High dose corticosteroids are usually given immediately post-transplantation and for initial treatment of rejection. Steroid induced psychiatric syndromes are common, complex, unpredictable, and range from subtle mood changes to full blown affective syndromes and frank psychosis. Mild symptoms of agitation, anxiety, distractibility, fear, insomnia, lethargy, labile mood, and restlessness occur in 20-30 per cent and severe symptoms of affective syndromes, psychosis and cognitive impairment in six per cent cases.\textsuperscript{44} Treatment includes steroid dose reduction or discontinuation. If steroid dose reduction is not feasible, symptomatic treatment with antipsychotics, mood stabilizer or anti-depressants is recommended.\textsuperscript{44}

Azathioprine: There are reports of depressive symptoms induced by azathioprine in combination, with cyclosporine and prednisone in particular.\textsuperscript{42}

Mycophenolate mofetil: CNS adverse effects - anxiety, depression, delirium, seizures, agitation, psychosis and somnolence - have been recorded in 3-20 per cent recipients of mycophenolate.\textsuperscript{42}

**Management of psychiatric disorders**

The risk for psychiatric disorders rises during organ transplantation and it adversely affects the OT outcome, compliance, morbidity, and mortality. Patients with mental health disorders, when adequately controlled and socially supported, have outcomes similar to the general transplant population.\textsuperscript{49} Hence, there is need for early recognition and management.

**Psychotropics**

Organ dysfunction during pre-transplant period changes the pharmacokinetics of psychotropic agents, requiring proper selection of the drug and the dose. Similarly in post-OT period, psychotropics selection is influenced by drug pharmacokinetics, adverse effects, and tolerability and drug-drug interactions. Studies on the treatment of psychiatric disorders in OT cases being limited, the decisions need to be based on a review of clinical and pharmacokinetic data.\textsuperscript{46-49}

**Selection of psychotropics in liver failure**

Antipsychotics are mainly metabolized by liver except for sulpiride, amisulpride and paliperidone. In mild-moderate liver disease all antipsychotics can be tried with caution, but in severe liver disease it is better to avoid those metabolised by liver.\textsuperscript{49} All antidepressants are also mainly metabolized by liver. TCAs can cause sedation and constipation, and SSRIs can prolong prothrombin time (PT). Escitalopram with minimal effects on hepatic enzymes and sertraline with minimal drug-drug interactions are SSRIs of choice, although clinical experience is limited. Serotonin norepinephrine reuptake inhibitors (SNRIs) can be used with dose reduction. Mirtazapine with its minimal effect on CYP enzymes system is a better choice for patients with insomnia and anorexia.\textsuperscript{46,48,49}

Mood stabilizers except for lithium and gabapentin are metabolized by liver, alter liver function test, especially during the first month but it is transient.\textsuperscript{49} Benzodiazepines (BZDs) lorazepam, oxazepam, temazepam have short half-life with no active metabolites. So these are the better choice among BZDs.\textsuperscript{49}

**Selection of psychotropics in renal failure**

Antipsychotics except for amisulpride and sulpiride can be used in standard doses but with caution. Drugs with anticholinergic properties may cause urinary retention, confusion, and hypotension and ziprasidone with a potential to cause prolonged QTc interval are
better avoided\textsuperscript{49}. Among antidepressants, there is no preferred agent. In severe renal impairment and anuria, dose adjustment is indicated\textsuperscript{46,48}. Benzodiazepines are mainly metabolized in liver. In ESRD dose reduction is generally not necessary except for midazolam and chlordiazepoxide whose active metabolites are excreted through kidney\textsuperscript{49}. Among mood stabilizers, lithium is excreted unchanged in urine up to 95 per cent and is a known nephrotoxic. Also, being small molecule lithium is readily dialyzed and entirely eliminated by dialysis. If lithium is to be used in ESRD because of non-response to other mood stabilizers, single dose (usually 600 mg) treatment is recommended after each dialysis session. Other mood stabilizers can be used with caution\textsuperscript{48,49}.

**Psychotherapy**

Empirical data regarding psychotherapeutic interventions among OT recipients are very limited. Procedures that are commonly employed in clinical settings are group therapy, educational groups, support groups, internet based regimen and mentorship programme\textsuperscript{50}. A study has shown both individual and group psychotherapy to be beneficial and individual therapy to be better than group therapy. Both decrease the negative affect, increase happiness and QOL\textsuperscript{51}. Another study showed telephone-based emotional support and cognitive behaviour therapy to increase QOL and social network\textsuperscript{32}. Internet based intervention improved compliance, QOL, follow up care and decreased anxiety, depressive symptoms in both patients and caregivers among heart transplant recipients\textsuperscript{53}. Mentorship by an already transplanted recipient augmented patient care by providing information and support from a peer perspective\textsuperscript{54}.

**Drug-drug interactions between immuno suppressants and psychotropics**

Commonly used immunosuppressants like steroids, tacrolimus, cyclosporine and mycophenolate have narrow therapeutic index and are mainly metabolized by cytochrome P450 3A4. Specific cytochrome P450 3A4 inhibitors in decreasing order are: fluvoxamine, nefazodone>fluoxetine>sertraline, TCAs, paroxetine >venlafaxine\textsuperscript{55}. There are many case reports of tacrolimus and cyclosporine toxicity, when fluvoxamine and nefazodone were added to treat depression\textsuperscript{55}. In contrast, many case reports favour safe use of other antidepressants in combination with immunosuppressants. Cyclosporine increases lithium resorption by proximal tubule, so it is mandatory to monitor lithium level in patients on cyclosporine. Disulfiram may interact with the alcohol vehicle of cyclosporine and its active metabolite is an inhibitor of CYP450 3A4\textsuperscript{55}.

**Burden among caregivers**

Dependency of transplant recipients on caregivers for everything including self-care, treatment adherence, finance, transportation, and emotional support, put them under stress. Heavy burden on caregivers and negative coping styles are shown to be associated with higher levels of depression\textsuperscript{56}. In a study on caregivers of lung OT cases stress related depressive and anxiety symptoms have been reported in 82 per cent caregivers. Acute illness stage was rated more stressful than rehabilitation stage. Compared to spouses, mothers were particularly vulnerable as support persons\textsuperscript{57}. Another study on heart transplantation group showed employment status and caregivers’ physical health as strong predictors of post-OT distress. Increased distress was noted in early post-OT but not in later months\textsuperscript{58}. In a study on renal OT group, all caregivers perceived burden, more if the patient was a male\textsuperscript{59}. There was no relationship between caregiver burden score and patients’ marital status, education level, operation time, age, donor type (cadaveric or living)\textsuperscript{59}. The data regarding intervention studies are lacking; the available data show group therapy, support group and web based interventions as useful strategies in alleviating distress among caregivers.

**Issues of living donor**

In view of the organ shortage living organ donation is an alternative to deceased organ donation. In the USA, related and unrelated living donors constitute 44 per cent of all organ donors. Of these, 95 per cent are kidney donors, four per cent are liver donors, and the remaining one per cent are pancreas, intestine and lung donors\textsuperscript{60}. Donors with altruistic motivation, no ambivalence, good understanding about risks and benefits of donation, no history of psychiatric illness or substance abuse, good family support and financial stability are known to have better outcome. In a systematic review of 51 studies, 5139 living kidney donors assessed after four years showed that the majority experienced no depression (77-95%) or anxiety (86-94%), reported unchanged or improved relationship with the recipient (86-100%), and reported psychological benefits from donation in terms of gratification of helping the needy and experiencing increase self-esteem. Though most scored high on QOL measures, a small proportion
had adverse psychosocial outcomes. Another study reported a reasonable QOL among lobar lung donors, despite a subjective decline in exercise tolerance. In a six month follow up study of 392 liver donors, 16 (4.1%) had one or multiple psychiatric complications [12 depression, 2 anxiety, 2 substance abuse, and bipolar affective disorder (BPAD), 1 accidental overdose, insomnia, crying episodes, and worsening of obsessive compulsive disorder (OCD) each]. It was not clearly known if the donors were inherently more prone to psychiatric problems and had concealed this during evaluation or hepatectomy; or the psychiatric problems were a consequence of hepatectomy which is a more invasive procedure with more post-operative medical complications.

Indian scenario

There is very limited research from India on psychiatric issues related to OT. An early study reported negative emotions among kidney recipients and donors. Among the recipients the common emotions included anxiety-depression and resentment during dialysis and perioperative period, and anxiety, dependency-frustration, body image change and decreased libido on a long term basis. Among the donors, hostility towards family members, ambivalence towards recipients, adjustment problem at work and with spouse, anxiety about surgical procedures were recorded pre- and during OT period and excessive worry about physical symptoms of recipients, depression and hypochondriacal symptoms post-OT. A study with live kidney donors showed their morbidity, mortality and QOL remained unchanged. Cognitive profile and depression were studied in 30 renal transplant patients which showed depression rate of 87 and 57 per cent one month before and three month after transplantation and mean IQ increased from 88.5 to 101 following transplantation especially with respect to concentration and visual organization. In a six month to six year follow up of 50 male kidney recipients psychiatric illness was noted in 46 per cent of patients and it was more common among unmarried, high education group and high socio-economic status.

Conclusion

Transplantation is a challenging process for patients, caregivers, and medical professionals. It is associated with substantial emotional distress with tremendous lifestyle changes and psychological stresses. Psychosocial evaluation, considered to be a gate pass for transplantation, carries great significance. Depression and anxiety are the most common psychiatric disorders among the OT candidates and recipients. Currently, there is no general consensus on how to select/reject cases for transplantation with affective disorders, psychotic disorders, personality disorders and substance dependence. As the psychiatric disorders predict poor outcome both pre- and post-OT, it calls for an aggressive management. Immunosuppressants related neuropsychiatric side effects and drug-drug interactions with psychotropics should be kept in mind while treating psychiatric disorders. Caregivers also carry significant distress and need support. A psychiatrist as a member of the OT team can be of help for better outcome of OT.

References

1. The Transplantation of Human Organs Act 1994. New Delhi: Ministry of Law, Justice and Company Affairs (Legislative Department); 11th July 1994. No. 42.
2. Dew MA, Switzer GE, DiMartini AF, Matukaitis J, Fitzgerald MG, Kormos RL. Psychosocial assessments and outcomes in organ transplantation. Prog Transplant 2000; 10: 239-59.
3. Bravata DM, Olkin I, Barnato AE, Kefee EB, Owens DK. Health-related quality of life after liver transplantation: a meta-analysis. Liver Transpl Surg 1999; 5: 318-31.
4. Dew MA, Switzer GE, Goycoolea JM, Allen AS, DiMartini AF, Kormos RL, et al. Does transplantation produce quality of life benefits? A quantitative analysis of the literature. Transplantation 1997; 64: 1261-73.
5. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009; 6: e1000097.
6. United Network of Organ Sharing and Scientific Registry of Transplant Recipients. Available from: http://www.unos.org/data, accessed on December 21, 2014.
7. Dimartini AF, Dew MA, Crone CC. Organ transplantation. In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan & Sadock’s comprehensive textbook of psychiatry. 9th ed. Philadelphia: Lippincott Williams and Wilkins; 2009. p. 2441-55.
8. Levenson J, Olbrisch ME. Psychosocial screening and selection of candidates for organ transplantation. In: The transplant patient. Cambridge, UK, Cambridge University Press; 2000. p. 23.
9. Dew MA, DiMartini AF, De Vito Dabbs A, Myaskovsky L, Steel J, Unruh M, et al. Rates and risk factors for non adherence to the medical regimen after adult solid organ transplantation. Transplantation 2007; 83: 858-73.
10. Denhaerynck K, Dobbels F, Cleemput I, Desmyterre A, Schäfer-Keller P, Schaub S, et al. Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review. Transpl Int 2005; 18: 1121-33.
11. Modlin C, Flechner S, Goormastic M, Goldfarb DA, Papajcik D, Mastroianni B, et al. Should obese patients lose weight
before receiving a kidney transplant. Transplantation 1997; 64: 599-604.

12. Grady K, White-Williams C, Naftel D, Costanzo MR, Pitts D, Rayburn B, et al. Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: A multi-institutional study of preoperative weight-height indices. J Heart Lung Transplant 1999; 18: 750-63.

13. Patel M. The effect of dietary intervention on weight gains after renal transplantation. J Ren Nutr 1998; 8: 137-41.

14. Schmid-Mohler G, Fehr T, Witschi P, Albiez T, Biotti B, Spirig R. Development of an evidence-based self-management programme for patients in the first year after renal transplantation with a focus on prevention of weight gain, physical exercise and drug adherence. Pfleger 2013; 26: 191-205.

15. Trumper A, Appleby L. Psychiatric morbidity in patients undergoing heart, heart and lung, or lung transplantation. J Psychosom Res 2001; 50: 103-5.

16. Olbrisch ME, Benedict SM, Ashe K, Levenson JL. Psychological assessment and care of organ transplant patients. J Consult Clin Psychol 2002; 70: 771-83.

17. Dew MA, DiMartini AF. Psychological disorders and distress after adult cardiothoracic transplantation. J Cardiovasc Nurs 2005; 20: 51-66.

18. Singh N, Gayowski T, Wagener MM, Marino IR. Depression in patients with cirrhosis. Impact on outcome. Dig Dis Sci 1997; 42: 1421-7.

19. Corruble E, Barry C, Varescon I, Falissard B, Castaing D, Samuel D. Depressive symptoms predict long-term mortality after liver transplantation. J Psychosom Res 2011; 71: 32-7.

20. DiMartini A, Dew MA, Chaiffetz D, Fitzgerald MG, Devera ME, Fontes P. Early trajectories of depressive symptoms after liver transplantation for alcoholic liver disease predicts long-term survival. Am J Transplant 2011; 11: 1287-95.

21. Kapfhammer HP, Rothenhäusler HB, Krauseneck T, Stoll C, Schelling G. Posttraumatic stress disorder and health-related quality of life in long-term survivors of acute respiratory distress syndrome. Am J Psychiatry 2004; 161: 45-52.

22. DiMartini AF, Crone C, Fireman M, Dew MA. Psychiatric aspects of organ transplantation in critical care. Crit Care Clin 2008; 24: 949-81.

23. Dew MA, Kormos RL, Roth LH, Murali S, DiMartini A, Griffith BP. Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation. J Heart Lung Transplant 1999; 18: 540-62.

24. Baranyi A, Krauseneck T, Rothenhäusler HB. Posttraumatic stress symptoms after solid-organ transplantation: preoperative risk factors and the impact on health-related quality of life and life satisfaction. Health Qual Life Outcomes 2013; 11: 111.

25. Levenson J, Olbrisch ME. Psychosocial screening and selection of candidates for organ transplantation. In: Trzepacz PT, DiMartini AF, editors. The transplant patient. Cambridge, England: Cambridge University Press; 2000. p. 21-41.

26. Coffman KL, Crone C. Rational guidelines for transplantation in patients with psychotic disorders. Curr Opin Organ Transplant 2002; 7: 385-8.

27. Chacko RC, Harper RG, Gotto J, Young J. Psychiatric interview and psychometric predictors of cardiac transplant survival. Am J Psychiatry 1996; 153: 1607-12.

28. Dobbs F, Put C, Vanhaecke J. Personality disorders: a challenge for transplantation. Prog Transplant 2000; 10: 226-32.

29. Bunzel B, Laederach-Hofmann K. Solid organ transplantation: are there predictors for posttransplant noncompliance? A literature overview. Transplantation 2000; 70: 711-6.

30. Coffman KL, Hoffman A, Sher L, Rojier S, Vierling J, Makowka L. Treatment of the postoperative alcoholic liver transplant recipient with other addictions. Liver Transpl Surg 1997; 3: 322-7.

31. Panocchia N, Bossola M, Vivanti G. Transplantation and mental retardation: what is the meaning of a discrimination? Am J Transplant 2010; 10: 727-30.

32. Parker R, Armstrong MJ, Corbett C, Day EJ, Neuberger JM. Alcohol and substance abuse in solid-organ transplant recipients. Transplantation 2013; 96: 1015-24.

33. Pungnapong S, Manzarbeitia C, Ortiz J, Reich DJ, Araya V, Rothstein KD, et al. Cigarette smoking is associated with an increased incidence of vascular complications after liver transplantation. Liver Transpl 2002; 8: 582-7.

34. Jain AB, Fung J. Alcoholic liver disease and transplantation. Transplant Proc 2003; 35: 358-60.

35. Neuberger J, Tang H. Relapse after transplantation: European studies. Liver Transpl Surg 1997; 3: 275-9.

36. Dew MA, DiMartini AF, Steel J, De Vito Dabbs A, Myaskovsky L, Unruh M, et al. Meta-analysis of risk for relapse to substance use after transplantation of the liver or other solid organs. Liver Transpl 2008; 14: 159-72.

37. Coffman KL, Hoffman A, Sher L, Rojier S, Vierling J, Makowka L, et al. Treatment of the postoperative alcoholic liver transplant recipient with other addictions. Liver Transpl Surg 1997; 3: 322-7.

38. DiMartini A, Weinrieb R, Fireman M. Liver transplantation in patients with alcohol and other substance use disorders. Psychiatr Clin North Am 2002; 25: 195-209.

39. Fireman M. Outcome of liver transplantation in patients with alcohol and poly-substance dependence. Presented at Research Society on Alcoholism: Symposium on Liver Transplantation for the Alcohol Dependent Patient. Denver, CO, June 2000.

40. Foster PF, Fabrega F, Karademir S, Sankary HN, Mital D, Williams JW, et al. Prediction of abstinence from ethanol in alcoholic recipients following liver transplantation. Hepatology 1997; 25: 1469-77.

41. Newton SE. Recidivism and return to work posttransplant. J Subst Abuse Treat 1999; 17: 103-8.

42. DiMartini AF, Dew MA, Trzepacz PT. Organ transplantation. In: Levenson JL, editor. Textbook of psychosomatic medicine. Washington, DC: American Psychiatric Press; 2005. p. 675-700.

43. Corbett C, Armstrong MJ, Neuberger J. Tobacco smoking and solid organ transplantation. Transplantation 2012; 94: 979-87.
44. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc 2006; 81 : 1361-7.
45. Corbett C, Armstrong MJ, Parker R, Webb K, Neuberger JM. Mental health disorders and solid-organ transplant recipients. Transplantation 2013; 96: 593-600.
46. Crone CC, Gabriel GM. Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. Clin Pharmacokinet 2004; 43 : 361-94.
47. Trzepacz PT, DiMartini A, Tringali R. Psychopharmacologic issues in organ transplantation. Part I: Pharmacokinetics in organ failure and psychiatric aspects of immunosuppressants and anti-infectious agents. Psychosomatics 1993; 34 : 199-207.
48. Trzepacz PT, DiMartini A, Tringali RD. Psychopharmacologic issues in organ transplantation. Part 2: Psychopharmacologic medications. Psychosomatics 1993; 34 : 290-8.
49. Taylor D, Paton C, Kapur S. Use of psychotropics in special patient groups. In: The Maudsley prescribing guidelines, 10th ed. UK: MBG Books; 2010. p. 335-463.
50. Engle D. Psychosocial aspects of the organ transplant experience: What has been established and what we need for the future. J Clin Psychol 2001; 57 : 521-49.
51. Abbey S, Farrow S. Group therapy and organ transplantation. Int J Group Psychother 1998; 48 : 163-85.
52. Napolitano MA, Babyak MA, Palmer S, Tapson V, Davis RD, Blumenthal JA, et al. Effects of a telephone-based psychosocial intervention for patients awaiting lung transplantation. Chest 2002; 122 : 1176-84.
53. Dew MA, Goycoolea JM, Harris RC, Lee A, Zomak R, Dunbar-Jacob J, et al. An internet-based intervention to improve psychosocial outcomes in heart transplant recipients and family caregivers: development and evaluation. J Heart Lung Transplant 2004; 23 : 745-58.
54. Wright L, Pennington JJ, Abbey S, Young E, Haines J, Ross H. Evaluation of a mentorship program for heart transplant patients. J Heart Lung Transplant 2001; 20 : 1030-3.
55. Fireman M, DiMartini AF, Armstrong SC, Cozza KL. Med-psych drug interactions update: immunosuppressants. Psychosomatics 2004; 45 : 354-60.
56. Goetzinger AM, Blumenthal JA, O’Hayer CV, Babyak MA, Hoffman BM, Ong L, et al. Stress and coping in caregivers of patients awaiting solid organ transplantation. Clin Transplant 2012; 26 : 97-104.
57. Ullrich G, Jänsch H, Schmidt S, Strüber M, Niedermeyer J. The experience of the support person involved in a lung transplantation programme: results of a pilot study. Eur J Med Res 2004; 9 : 555-652.
58. Canning RD, Dew MA, Davidson S. Psychological distress among caregivers to heart transplant recipients. Soc Sci Med 1996; 42 : 599-608.
59. Eiroulahi B, Taheri S, Nemati E, Abbasszadeh S, Pourfarziani V, Nourbala MH. Burden among care-givers of kidney transplant recipients and its associated factors. Saudi J Kidney Dis Transpl 2009; 20 : 30-4.
60. Clemens KK, Thiessen-Philbrook H, Parikh CR, Yang RC, Karley ML, Boudville N, et al. Psychosocial health of living kidney donors: a systematic review. Am J Transplant 2006; 6 : 2965-77.
61. Prager LM, Wain JC, Roberts DH, Gins L. Medical and psychologic outcome of living lobar lung transplant donors. J Heart Lung Transplant 2006; 25 : 1206-12.
62. Trotter JF, Hill-Callahan MM, Gillespie BW, Nielsen CA, Saab S, Shrestha R, et al. Severe psychiatric problems in right hepatic lobe donors for living donor liver transplantation. Transplantation 2007; 83 : 1506-8.
63. Kuruvilla K, Mohan Rao M, Johny KV. Psychiatric aspects of renal transplantation - some observations on recipients. Indian J Psychiatry 1976; 17 : 26-32.
64. Kuruvilla K, Pandey AP, Shastry JCM. Psychiatric aspects of renal transplantation - observations on donors. Indian J Psychiatry 1979; 21 : 155-8.
65. Sahay M, Narayen G, Anuradha. Risk of live kidney donation-Indian perspective. J Assoc Physicians India 2007; 55 : 267-70.
66. Pawar AA, Rathod J, Chaudhury S, Saxena SK, Saldanha D, Ryali VSSR, et al. Cognitive and emotional effects of renal transplantation. Indian J Psychiatry 2006; 48 : 21-6.
67. Chaturvedi SK, Pant VLN. Psychiatric aspects of renal transplantation. Indian J Psychiatry 1985; 27 : 77-81.

Reprint requests: Dr Surendra Kumar Matto, Department of Psychiatry, Postgraduate Institute of Medical Education & Research, Chandigarh 160 012, India
E-mail: skmattoo@gmail.com